Article

EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive-variant prostate cancer

2024-09-11

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> EZH2 promotes aggressive-variant prostate cancer (AVPC) progression via histone H3-Lysine-27 tri-methylation (H3K27me3). We hypothesize that epigenetic reprogramming via EZH2 inhibitors (EZH2i) improves the efficacy of chemotherapy in AVPC. <h4>Methods</h4> We studied the expression of EZH2 in clinical prostate cancer cohorts (bioinformatics). We determined the effect of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5c910c1e-acf2-56ec-a6e5-56cba79c117d
DOI: 10.1101/2024.09.06.611612

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive-variant prostate cancerDOI 10.1101/2024.09.06.611612Read

A non-canonical EZH2 function sensitizes solid tumors to genotoxic stressSemantic proximity Read

Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor TypesSemantic proximity Read

Pharmacological targeting of EED is an effective therapeutic strategy in cellular models of incurable neuroendocrine prostate cancerSemantic proximity Read

Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypesSemantic proximity Read

Enzalutamide-induced signatures revealed by epigenetic plasticity using single-cell multi-omics sequencing in prostate cancerSemantic proximity Read

Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines.Semantic proximity Read

BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotypeSemantic proximity Read

Establishment and characterization of a novel treatment‐related neuroendocrine prostate cancer cell line KUCaP13Semantic proximity Read

EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico AnalysisSemantic proximity Read

A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformationSemantic proximity Read

A Polycomb Repression Signature in Metastatic Prostate Cancer Predicts Cancer OutcomeSemantic proximity Read

Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).Semantic proximity Read